157 related articles for article (PubMed ID: 9165691)
21. Reduction of pentagastrin stimulated acid output: a suitable method to predict efficacy of an irreversible proton pump inhibitor in peptic ulcer disease?
Bliesath H; Simon B; Hartmann M; Müller P; Schneider A; Lühmann R; Wurst W
Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):439. PubMed ID: 1337063
[No Abstract] [Full Text] [Related]
22. [Are proton pump inhibitors safe?].
Creutzfeldt W
Internist (Berl); 1994 Dec; 35(12):1137-46. PubMed ID: 7883517
[No Abstract] [Full Text] [Related]
23. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.
Miehlke S; Madisch A; Kirsch C; Lindner F; Kuhlisch E; Laass M; Knoth H; Morgner A; Labenz J
Aliment Pharmacol Ther; 2005 Apr; 21(8):963-7. PubMed ID: 15813831
[TBL] [Abstract][Full Text] [Related]
24. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours.
Netzer P; Gaia C; Sandoz M; Huluk T; Gut A; Halter F; Hüsler J; Inauen W
Am J Gastroenterol; 1999 Feb; 94(2):351-7. PubMed ID: 10022628
[TBL] [Abstract][Full Text] [Related]
25. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.
Pisegna JR; Martin P; McKeand W; Ohning G; Walsh JH; Paul J
Am J Gastroenterol; 1999 Oct; 94(10):2874-80. PubMed ID: 10520836
[TBL] [Abstract][Full Text] [Related]
27. Oral buffered esomeprazole is superior to i.v. pantoprazole for rapid rise of intragastric pH: a wireless pH metry analysis.
Banerjee R; Reddy DN; Guda NM; Kalpala R; Mahurkar S; Darisetty S; Rao GV
J Gastroenterol Hepatol; 2010 Jan; 25(1):43-7. PubMed ID: 19874444
[TBL] [Abstract][Full Text] [Related]
28. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
Goldstein JL; Miner PB; Schlesinger PK; Liu S; Silberg DG
Aliment Pharmacol Ther; 2006 Apr; 23(8):1189-96. PubMed ID: 16611280
[TBL] [Abstract][Full Text] [Related]
29. The effect of intravenous pantoprazole and ranitidine for improving preoperative gastric fluid properties in adults undergoing elective surgery.
Memiş D; Turan A; Karamanlioglu B; Saral P; Türe M; Pamukçu Z
Anesth Analg; 2003 Nov; 97(5):1360-1363. PubMed ID: 14570652
[TBL] [Abstract][Full Text] [Related]
30. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
31. Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans.
Londong W
Aliment Pharmacol Ther; 1994; 8 Suppl 1():39-46. PubMed ID: 8180293
[TBL] [Abstract][Full Text] [Related]
32. Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers.
Simon B; Müller P; Hartmann M; Bliesath H; Lühmann R; Huber R; Bohnenkamp W; Wurst W
Z Gastroenterol; 1990 Sep; 28(9):443-7. PubMed ID: 2177296
[TBL] [Abstract][Full Text] [Related]
33. Lack of pantoprazole drug interactions in man.
Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
Int J Clin Pharmacol Ther; 1994 Aug; 32(8):385-99. PubMed ID: 7981922
[TBL] [Abstract][Full Text] [Related]
34. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
Howden CW; Ballard ED; Koch FK; Gautille TC; Bagin RG
J Clin Gastroenterol; 2009 Apr; 43(4):323-6. PubMed ID: 18758373
[TBL] [Abstract][Full Text] [Related]
35. Intravenous proton pump inhibitors.
Baker DE
Rev Gastroenterol Disord; 2006; 6(1):22-34. PubMed ID: 16520709
[TBL] [Abstract][Full Text] [Related]
36. Current status of acid pump antagonists (reversible PPIs).
Wurst W; Hartmann M
Yale J Biol Med; 1996; 69(3):233-43. PubMed ID: 9165692
[TBL] [Abstract][Full Text] [Related]
37. [Proton pump inhibitors: Pantoprazole].
Takeuchi K; Hase S
Nihon Rinsho; 2002 Feb; 60 Suppl 2():655-60. PubMed ID: 11979865
[No Abstract] [Full Text] [Related]
38. The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.
Törüner M; Bektaş M; Cetinkaya H; Soykan I; Ozden A
Turk J Gastroenterol; 2004 Dec; 15(4):225-8. PubMed ID: 16249975
[TBL] [Abstract][Full Text] [Related]
39. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study.
Wilder-Smith CH; Röhss K; Bondarov P; Hallerbäck B; Svedberg LE; Ahlbom H
Aliment Pharmacol Ther; 2004 Nov; 20(10):1099-104. PubMed ID: 15569112
[TBL] [Abstract][Full Text] [Related]
40. Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux.
Wo JM; Koopman J; Harrell SP; Parker K; Winstead W; Lentsch E
Am J Gastroenterol; 2006 Sep; 101(9):1972-8; quiz 2169. PubMed ID: 16968502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
